Cellvizio by Mauna Kea Technologies

Cellvizio by Mauna Kea Technologies Cellvizio is the real-time in vivo cellular imaging platform that revolutionizes the way physicians

Mauna Kea Technologies is a global medical device company that manufactures and sells Cellvizio®, the real-time in vivo cellular imaging platform. This technology uniquely delivers in vivo cellular visualization which enables physicians to monitor the progression of disease over time, assess point-in-time reactions as they happen in real-time, classify indeterminate areas of concern, and guide surgical interventions. The Cellvizio platform is used globally across a wide range of medical specialties and is revolutionizing the way physicians diagnose and treat patients — making a transformative change in medicine.

02/10/2026

We are proud to announce that Cellvizio® and its associated probes have officially received CE Mark certification under the European Medical Device Regulation (MDR). Mauna Kea Technologies is the only endomicroscopy company to obtain this certification under the new European regulation.

This major regulatory milestone reinforces our commitment to the highest standards of safety and clinical performance, ensuring continued access to our Cellvizio platform across Europe.

Read the full press release here: https://hubs.la/Q042xVrw0

According to the World Health Organization (WHO), “between 30% and 50% of cancer deaths could be prevented by modifying ...
02/10/2026

According to the World Health Organization (WHO), “between 30% and 50% of cancer deaths could be prevented by modifying or avoiding key risk factors.” Addressing risk factors through early detection is core to our mission at Mauna Kea Technologies, where we strive to transform patient management and care.

Learn more: https://hubs.la/Q041khMY0

02/04/2026

Today we announce key organizational changes to accelerate our international growth. Building on strong 2025 momentum, we've appointed Benoit Chardon as Fractional Chief Commercial Officer to lead the global scale-up of outside the United States.

Following CellTolerance's €1 million sales milestone in 2025, we're entering a focused expansion phase across Europe, the Middle East, and Australia. Simultaneously, we're advancing our pancreatic cyst characterization franchise, leveraging the recent European Society of Gastrointestinal Endoscopy (ESGE) technical guidelines inclusion and strong clinical momentum.

Read the full PR: https://hubs.la/Q041Tsmt0

On World Cancer Day, we join the global effort to raise awareness and unite against cancer; the number one leading cause...
02/04/2026

On World Cancer Day, we join the global effort to raise awareness and unite against cancer; the number one leading cause of death. At Mauna Kea Technologies, we are committed to transforming the way cancer is diagnosed and managed. Learn how can make early cancer detection a reality to improve patient outcomes and long-term prognosis.

To learn more, visit: https://hubs.la/Q041mw6C0

More highlights from our Workshop at Sozialstiftung Bamberg! Three live cases demonstrated cellular reactions to food ...
02/03/2026

More highlights from our Workshop at Sozialstiftung Bamberg! Three live cases demonstrated cellular reactions to food triggers, sparking insightful discussions and collaborative learning with exceptional clinicians advancing integrated care.

To learn more about how Prof. Dr. med. Langhorst uses CellTolerance to detect food intolerances and provide lasting relief, visit: https://hubs.la/Q041BqT20

An educational day at the CellTolerance Workshop in Bamberg! It was a privilege to engage with such dedicated participan...
02/02/2026

An educational day at the CellTolerance Workshop in Bamberg! It was a privilege to engage with such dedicated participants and witness the impact of the CellTolerance test through three insightful live cases demonstrating how cells react to specific food triggers. Seeing this clinical application in real time underscores the importance of innovation in modern medicine.

A huge thank you to Prof. Dr. med. Jost Langhorst and the entire team at Sozialstiftung Bamberg for their incredible hospitality and clinical expertise. Collaborative days like these drive the future of integrated care! For a deeper look at how Prof. Dr. med. Langhorst uses CellTolerance to detect underlying food intolerances and provide lasting relief, visit: https://hubs.la/Q041mqsp0

01/27/2026

Traditional testing often relies on delayed markers. The test provides immediate diagnostic clarity by revealing cellular-level gut reactions to food in real-time. No more guesswork. Identify functional mucosal barrier impairment with cellular precision to give patients answers and relief, faster.

Learn more: https://hubs.la/Q040vrbP0

01/22/2026

The free app is easy to use, from anywhere. Enhance your image pattern recognition skills and use samples from our video library as references to compare your cases with examples from a wide range of indications.

01/15/2026

Today we announce a breakthrough fourth quarter, driven by significant U.S. expansion and the growth of .

Key performance highlights include a 19% surge in Q4 revenue, fueled by powerful momentum in pancreatic cyst indication and CellTolerance’s milestone €1M in global FY2025 sales. We further solidified U.S. market leadership by securing four new system sales in Q4 and initiating a strategic partnership with TaeWoong Medical USA. Driven by this record-breaking performance in the U.S. and enhanced operational visibility, we enter 2026 focused and ready for the year ahead.

Read the full PR: https://hubs.la/Q03_0XXW0

Huge milestone for the Cellvizio by Mauna Kea Technologies team as we support Dr. Bharat Panuganti in the first laryngea...
01/12/2026

Huge milestone for the Cellvizio by Mauna Kea Technologies team as we support Dr. Bharat Panuganti in the first laryngeal cases at Barnes-Jewish Hospital. Conventional imaging shows the "what," but shows the "why" at a cellular level. Better margins, better decisions, better outcomes. Seeing this level of precision in the hands of such a skilled team is inspiring!

Physicians, there is no time like the new year to reconsider what technologies will best support your patient management...
01/07/2026

Physicians, there is no time like the new year to reconsider what technologies will best support your patient management in the months to come.

Make the most of your new year’s resolution and consider how Cellvizio real-time, in vivo cellular imaging could revolutionize your practice: https://hubs.ly/Q03ZSzB10

01/01/2026

What a remarkable year 2025 has been, made possible by your support. In 2026, we're committed to setting new standards in care with precision and purpose. Thank you for being part of our journey. Together, we can .
Happy New Year!

Address

24 Denby Road, Suite 140
Boston, MA
02134

Opening Hours

Monday 8:30am - 5pm
Tuesday 8:30am - 5pm
Wednesday 8:30am - 5pm
Thursday 8:30am - 5pm
Friday 8:30am - 5pm

Website

Alerts

Be the first to know and let us send you an email when Cellvizio by Mauna Kea Technologies posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Our Story

Mauna Kea Technologies is a global medical device company focused on eliminating uncertainties related to the diagnosis and treatment of cancer and other diseases thanks to real time in vivo microscopic visualization. The Company’s flagship product, Cellvizio®, has received clearance/approval in a wide range of applications in more than 40 countries, including the United States, Europe, Japan, China, Canada, Brazil and Mexico.